Yacktman Asset Management LP Boosts Holdings in Embecta Corp. $EMBC

Yacktman Asset Management LP raised its position in Embecta Corp. (NASDAQ:EMBC) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,373,386 shares of the company’s stock after acquiring an additional 16,069 shares during the quarter. Yacktman Asset Management LP owned approximately 4.06% of Embecta worth $22,998,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new position in Embecta in the first quarter worth approximately $154,000. Principal Financial Group Inc. lifted its stake in Embecta by 3.4% in the first quarter. Principal Financial Group Inc. now owns 289,605 shares of the company’s stock worth $3,692,000 after acquiring an additional 9,601 shares during the last quarter. Comerica Bank lifted its stake in Embecta by 65.7% in the first quarter. Comerica Bank now owns 50,641 shares of the company’s stock worth $646,000 after acquiring an additional 20,079 shares during the last quarter. Raymond James Financial Inc. raised its holdings in Embecta by 2.1% during the first quarter. Raymond James Financial Inc. now owns 326,156 shares of the company’s stock worth $4,158,000 after purchasing an additional 6,640 shares in the last quarter. Finally, Public Sector Pension Investment Board raised its holdings in Embecta by 28.2% during the first quarter. Public Sector Pension Investment Board now owns 184,319 shares of the company’s stock worth $2,350,000 after purchasing an additional 40,564 shares in the last quarter. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Price Performance

Shares of Embecta stock opened at $13.86 on Thursday. The firm’s fifty day simple moving average is $14.24 and its 200-day simple moving average is $12.28. The stock has a market capitalization of $810.67 million, a price-to-earnings ratio of 9.69, a PEG ratio of 0.75 and a beta of 1.10. Embecta Corp. has a 12 month low of $9.20 and a 12 month high of $21.48.

Embecta (NASDAQ:EMBC) last announced its earnings results on Friday, August 8th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.35. The business had revenue of $295.50 million for the quarter, compared to analysts’ expectations of $278.15 million. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 EPS. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Analysts anticipate that Embecta Corp. will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on EMBC shares. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th. BTIG Research reissued a “buy” rating and set a $25.00 price objective on shares of Embecta in a report on Friday, September 5th. Mizuho cut their price objective on shares of Embecta from $13.00 to $12.00 and set a “neutral” rating on the stock in a report on Wednesday, July 16th. Finally, Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Embecta currently has an average rating of “Hold” and an average price target of $19.00.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.